Thrombin/Antithrombin III Complex Formation in the Neonatal Respiratory Distress Syndrome
Authors:
- Patsy VeghPVPatsy Vegh
- Jeffrey WeitzJWJeffrey Weitz
- Marilyn JohnstonMJMarilyn Johnston
- Chris CacoCCChris Caco
- Robin RobertsRRRobin Roberts
- 1 April 1992
- journal article
- Published by Oxford University Press (OUP) in American Review of Respiratory Disease
- Vol. 145 (4_Part_1) , 767-770
Abstract
Intravascular and intra-alveolar thrombin generation may exacerbate the pulmonary hypertension and surfactant dysfunction that characterize the neonatal respiratory distress syndrome (RDS). Although low levels of the most important thrombin inhibitor, antithrombin III (AT III), have been reported in infants with RDS, direct evidence of increased intravascular thrombin generation has been lacking. Accordingly, the objective of this study was to determine whether thrombin generation is increased in severe neonatal RDS. Thirty-nine infants of 25 to 29 wk gestation with a clinical and radiologic diagnosis of RDS were enrolled in a prospective cohort study. Plasma levels of thrombln/antithrombin III complexes (TAT) and AT III activity, measured 36 to 72 h after birth, were related to RDS severity. Seventeen infants had severe RDS (mean airway pressure > 10 cm H2O or Fi O2 > 0.8), and 22 had mild or moderate disease. Mean birthweight (1,017 versus 1,054 g) and mean gestational age (27.8 versus 27.4 wk) were similar in both groups. The median TAT level in infants with severe RDS was significantly higher than that in patients with mild or moderate disease (10.7 and 4.0 µg/L, respectively; p < 0.001). In addition, the mean AT III activity in infants with severe RDS was significantly lower than that in less severely affected patiente (0.31 and 0.46 U/ml, respectively; p < 0.01). Considering the entire cohort, plasma TAT levels were inversely correlated with the arterial/alveolar oxygen tension ratio (r = −0.48, p = 0.0022) and the ventilator efficiency index (r = −0.51, p = 0.0011). The elevated TAT levels and reduced AT III activity in infants with severe RDS are consistent with increased thrombin generation and resulting AT III consumption. Therefore, to regulate thrombin activity, these infante may benefit from replacement therapy with AT III concentrate.Keywords
This publication has 10 references indexed in Scilit:
- Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein.Journal of Clinical Investigation, 1990
- Surfactant for the Treatment of Respiratory Distress SyndromeAmerican Review of Respiratory Disease, 1987
- Mechanisms of Thrombin-induced Lung Vascular Injury and EdemaAmerican Review of Respiratory Disease, 1987
- Development of the human coagulation system in the full-term infantBlood, 1987
- Double-Blind, Randomized Trial of a Calf Lung Surfactant Extract Administered at Birth to Very Premature Infants for Prevention of Respiratory Distress SyndromePediatrics, 1985
- Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapyBlood, 1982
- Immunologic Studies of Antithrombin III Heparin Cofactor in the NewbornThrombosis and Haemostasis, 1978
- Hypercoagulability in Premature Infants with Special Reference to the Respiratory Distress Syndrome and HemorrhageNeonatology, 1971
- DISSEMINATED INTRAVASCULAR COAGULATION IN THE NEWBORNPediatrics, 1969
- STUDIES ON HYALINE MEMBRANE DISEASEPediatrics, 1966